Hepatitis Headlines

HCV Reinfection Rates Examined Following Successful Treatment

HCV Reinfection Rates Examined Following Successful Treatment

In order to determine HCV reinfection rates following sustained virologic response (SVR) in the overall population as well as in PWID, the study authors analyzed data obtained from a population-based study that included >1.7 million people that were tested for HCV.

Real-World Data Show Rising HCV Epidemic Among Young Adults

Real-World Data Show Rising HCV Epidemic Among Young Adults

The study included 17,149,480 patients obtained from 2 national laboratory datasets who were screened between 2013 and 2016 based on an AB test.

HCV Treatment Linked to Reduced Risk of Incident CVD Events

HCV Treatment Linked to Reduced Risk of Incident CVD Events

ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) was utilized to identify all patients who received HCV treatment for at least 7 weeks as well as a propensity-score matched group who did not receive treatment.

Chronic Hepatitis C Infection and Parkinsonism: What's the Link?

Chronic Hepatitis C Infection and Parkinsonism: What's the Link?

In order to determine the association between CHC and parkinsonism, the study authors utilized the National Health Insurance Research Database in Taiwan to identify CHC patients between 2004 and 2012.

Hepatocellular Carcinoma Risk Following Antiviral Therapy for HCV Examined

Hepatocellular Carcinoma Risk Following Antiviral Therapy for HCV Examined

The retrospective study aimed to determine the risk of incident, or de novo, HCC following different regimens of antiviral therapy.

Does Obesity Impact Virological Response in HCV Patients on DAA Therapy?

Does Obesity Impact Virological Response in HCV Patients on DAA Therapy?

The review analyzed 168 patients treated with an oral DAA at a single center from 2015 to 2017.

Direct-Acting Antiviral Therapy Uptake Examined Among HCV Patients

Direct-Acting Antiviral Therapy Uptake Examined Among HCV Patients

The study utilized data from the Chronic Hepatitis Cohort Study, an observational cohort study, to assess demographic and clinical characteristics associated with DAA use.

Direct-Acting Antiviral Therapy Linked to Reduced Risk of Incident T2D in HCV Patients

Direct-Acting Antiviral Therapy Linked to Reduced Risk of Incident T2D in HCV Patients

The study compared US administrative claims data of HCV patients with ≥12 weeks of dispensed DAA therapy (N=17,848) to untreated HCV patients with follow-up data (N=108,350).

Glecaprevir/Pibrentasvir 8-Week Regimen Evaluated in Treatment-Naïve HCV Patients With Compensated Cirrhosis

Glecaprevir/Pibrentasvir 8-Week Regimen Evaluated in Treatment-Naïve HCV Patients With Compensated Cirrhosis

In EXPEDITION-8, 280 treatment-naïve HCV patients (genotypes 1, 2, 4, 5, and 6) with compensated cirrhosis were treated with Mavyret for 8-weeks; the primary efficacy measure was SVR12 rate.

DAA Treatment and Hepatic Fibrosis Improvement in HCV: What's the Link?

DAA Treatment and Hepatic Fibrosis Improvement in HCV: What's the Link?

The study aimed to determine whether direct-acting antiviral therapy reduced fibrosis and assessed whether any predictors of treatment failure existed at 1-year follow-up.

Sign Up for Free e-newsletters